Novel biofocused targeting of nucleoside analogues with cyclic RGD peptides as enhanced anticancer therapy


NOBITAN is aimed at the development of novel chemotherapeutic products exhibiting an enhanced safety and efficacy profile, through a selective targeting of inactive cytotoxic compounds toward tumor cells, and a smart release and local activation of the anticancer drug.

Project Budget: 967’000 €

Financial Framework: ERA-NET

Contract number: IUE/4066/2010

Start Date: 01/09/2011

End Date: 01/08/2013


Contact Manager: I. Alfany

This project has received funding from the European Union’s Seventh Programme for research, technological development and demonstration and from ACCIÓ – Generalitat de Catalunya.